Zacks Research Has Bearish Forecast for ACHC Q3 Earnings

Key Points

• Zacks Research has downgraded Acadia Healthcare's Q3 2025 earnings estimate from $0.86 to $0.74 per share, reflecting a negative outlook for the company's performance.
• Acadia Healthcare's stock has seen multiple target price reductions from various analysts, with Royal Bank of Canada lowering it from $43.00 to $28.00.
• Despite current challenges, Acadia Healthcare had a revenue increase of 9.2% year-over-year, reporting $869.23 million for the most recent quarter.

Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) - Zacks Research cut their Q3 2025 EPS estimates for Acadia Healthcare in a research note issued to investors on Tuesday, August 19th. Zacks Research analyst Team now expects that the company will post earnings of $0.74 per share for the quarter, down from their previous forecast of $0.86. The consensus estimate for Acadia Healthcare's current full-year earnings is $3.38 per share. Zacks Research also issued estimates for Acadia Healthcare's Q4 2025 earnings at $0.59 EPS, FY2025 earnings at $2.55 EPS, Q1 2026 earnings at $0.46 EPS, Q4 2026 earnings at $0.76 EPS, FY2026 earnings at $2.89 EPS, Q1 2027 earnings at $0.51 EPS and FY2027 earnings at $3.24 EPS.

Other equities analysts have also issued research reports about the stock. Stephens upgraded shares of Acadia Healthcare to a "hold" rating in a research report on Monday, June 2nd. Cowen restated a "buy" rating on shares of Acadia Healthcare in a research report on Thursday, August 7th. UBS Group lowered their price target on shares of Acadia Healthcare from $45.00 to $31.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Royal Bank Of Canada lowered their price target on shares of Acadia Healthcare from $43.00 to $28.00 and set an "outperform" rating for the company in a research report on Wednesday, August 13th. Finally, Mizuho lowered their price target on shares of Acadia Healthcare from $32.00 to $22.00 and set a "neutral" rating for the company in a research report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $40.77.

Acadia Healthcare Stock Performance

ACHC stock traded down $0.31 during trading on Thursday, hitting $21.86. 602,243 shares of the company's stock traded hands, compared to its average volume of 2,188,867. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.73. Acadia Healthcare has a 52 week low of $17.13 and a 52 week high of $82.40. The stock has a fifty day moving average price of $21.94 and a two-hundred day moving average price of $25.87. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of 14.50, a price-to-earnings-growth ratio of 4.42 and a beta of 0.88.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.12. Acadia Healthcare had a net margin of 4.31% and a return on equity of 8.34%. The firm had revenue of $869.23 million during the quarter, compared to analyst estimates of $839.59 million. During the same quarter in the previous year, the firm earned $0.91 earnings per share. The firm's revenue for the quarter was up 9.2% compared to the same quarter last year. Acadia Healthcare has set its FY 2025 guidance at 2.450-2.65 EPS.

Institutional Investors Weigh In On Acadia Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Abrams Bison Investments LLC lifted its holdings in Acadia Healthcare by 96.7% in the 2nd quarter. Abrams Bison Investments LLC now owns 3,580,000 shares of the company's stock valued at $81,230,000 after acquiring an additional 1,760,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Acadia Healthcare by 18.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,182,729 shares of the company's stock valued at $126,189,000 after acquiring an additional 486,395 shares during the last quarter. State Street Corp lifted its holdings in Acadia Healthcare by 3.2% in the 2nd quarter. State Street Corp now owns 3,095,775 shares of the company's stock valued at $70,243,000 after acquiring an additional 95,670 shares during the last quarter. Maverick Capital Ltd. lifted its holdings in Acadia Healthcare by 13.6% in the 2nd quarter. Maverick Capital Ltd. now owns 2,553,237 shares of the company's stock valued at $57,933,000 after acquiring an additional 306,314 shares during the last quarter. Finally, Hawk Ridge Capital Management LP lifted its holdings in Acadia Healthcare by 437.5% in the 1st quarter. Hawk Ridge Capital Management LP now owns 2,473,226 shares of the company's stock valued at $74,988,000 after acquiring an additional 2,013,126 shares during the last quarter.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.